| Category | Details |
| Definition | IBD is a group of chronic inflammatory conditions of the gastrointestinal tract, including Crohn’s disease (CD) and ulcerative colitis (UC). |
| Global Epidemiology | – 4.9 million cases of IBD globally |
| – IBD has an increasing prevalence in Westernized countries |
| – Strong association with genetic, environmental, and immune system factors. |
| Prevalence in Key Regions | –United States: Approximately 762,890 adults were affected by IBD in 2019, which is about 0.2% of the population. Estimates range from 2.4 to 3.1 million, depending on the data source, with a notable increase in prevalence over the years, particularly among certain demographic groups. |
| European Union: An estimated 2.5 million cases of IBD have been reported in Europe, with a prevalence of approximately 500 per 100,000 population in many Western countries. However, specific figures may vary by country and region. |
| –India: The prevalence of IBD is increasing, with estimates suggesting between 1.5 and 2 million cases as awareness and diagnosis improve in urban areas. |
| China: Approximately 1 million people are diagnosed with IBD, with rising rates attributed to dietary changes and lifestyle factors. |
| Caribbean: Estimated cases of IBD range from 50,000 to 100,000, with challenges related to limited access to advanced treatments for affected individuals. |
| Medicinal Cannabis Approvals | – United States (FDA): No specific cannabis product approved for IBD; ongoing trials for CBD and THC efficacy. |
| – Canada: Cannabis authorized for chronic pain and inflammation management, used off-label for IBD. |
| – European Union (EMA): Limited approvals; cannabinoid treatments in clinical trials for CD and UC. |
| – Australia (TGA): Approved CBD for inflammatory conditions; used off-label for IBD. |
| – Israel: Medical cannabis approved for Crohn’s disease and ulcerative colitis since 2013. |
| Therapeutic Cannabinoids | – CBD (Cannabidiol): Anti-inflammatory effects; reduces gut permeability and modulates immune responses. |
| – THC (Tetrahydrocannabinol): Eases abdominal pain and improves appetite; psychoactive effects limit chronic use. |
| – CBG (Cannabigerol): Emerging evidence supports its role in reducing gut inflammation and oxidative stress. |
| – THCV (Tetrahydrocannabivarin): Preclinical evidence suggests benefits in reducing intestinal inflammation. |
| Mechanism of Action | – CBD: Activates CB2 receptors to reduce inflammation and oxidative stress in the gut. |
| – THC: Binds to CB1 receptors to decrease visceral hypersensitivity and abdominal pain. |
| – CBG: Inhibits pro-inflammatory cytokines like IL-6 and TNF-alpha, promoting mucosal healing. |
| Key Clinical Studies | – Naftali et al., 2011: Cannabis improved quality of life and reduced Crohn’s Disease Activity Index (CDAI) scores. |
| – Irving et al., 2018: CBD-rich cannabis reduced inflammation in UC patients in placebo-controlled trials. |
| – Katchman et al., 2021: THC reduced abdominal pain severity and improved appetite in IBD patients. |
| – Lahat et al., 2013: Demonstrated significant improvements in Crohn’s symptoms with THC administration. |
| Dosage Guidelines | – CBD (Oral): Start at 20–40 mg/day; titrate as needed, with some sources suggesting higher doses up to 250 mg/day based on individual response. |
| – THC (Oral): Starting at 1–2.5 mg/day for abdominal pain relief is reasonable; gradual titration is recommended. |
| – CBG (Experimental): Preliminary studies suggest 10–20 mg/day for gut inflammation reduction. |
| Administration Methods | – Oral Capsules: Preferred for consistent dosing and chronic management of IBD symptoms. |
| – Sublingual Oils: Rapid absorption; useful for flare-ups. |
| – Inhalation: Rarely recommended due to dosing variability and psychoactive effects. |
| Adverse Effects | – CBD: Mild side effects include fatigue, diarrhea, and appetite changes; rare liver enzyme elevation. |
| – THC: Psychoactive effects at higher doses; risk of dependency and cognitive impairment with chronic use. |
| – CBG: Limited data; potential mild sedation and dry mouth reported in early trials. |
| Research Gaps | – Long-term studies on safety and efficacy of cannabinoids like CBG and THCV for IBD treatment are lacking. |
| – Interactions between cannabinoids and conventional IBD medications remain underexplored. |
| Opportunities in the Caribbean | – High Prevalence: Estimated ~50,000–100,000 cases in the Caribbean with unmet treatment needs. |
| – Cannabis Clinics: Establishing cannabinoid-focused clinics could address local needs and attract medical tourists. |
| – Research Hub: Leveraging regional expertise to develop cannabinoid-based therapies for IBD. |
